Haleon Stock News

UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.

Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing

Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interacti...

Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V.

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three months to September, below Visible Alpha consensus of 3.5% and broadly unchanged from the second quarter.

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include Sensodyne and Panadol, against a last close of 342.8p.

Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in ​the United States, the company said, capitalising on the rising ‌popularity of GLP-1 medication.